Oxford University’s AstraZeneca vaccine candidate, AZD1222, against coronavirus disease (Covid-19) has shown 70% efficacy on average, according to the newly published data of phase 2/3
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
